Literature DB >> 8238195

Expression of connexin-43 in human myometrium and leiomyoma.

J Andersen1, E Grine, C L Eng, K Zhao, R L Barbieri, J C Chumas, P R Brink.   

Abstract

OBJECTIVES: The expression of connexin-43 was examined in human leiomyomas and in autologous myometrium. STUDY
DESIGN: Indirect immunofluorescence was used to detect connexin-43 gap junctions in myometrial and leiomyoma tissues and in primary cultures. Immunoblot and Northern analyses were used to examine the levels of connexin-43 protein and cx43 messenger ribonucleic acid in primary cultures.
RESULTS: Connexin-43 gap junctions were detected in leiomyoma tissue from nonpregnant premenopausal women but not in autologous myometrial tissue. Connexin-43 gap junctions form spontaneously in primary cultures of myometrium and leiomyoma in the presence of 17 beta-estradiol. Fluorescent dye injection confirmed that the gap junctions were coupled in the primary cells. Connexin-43 protein and messenger ribonucleic acid levels generally were higher in leiomyoma cells compared with those of autologous myometrial cells. Steady-state levels of cx43 messenger ribonucleic acid decreased with addition of medroxyprogesterone acetate to the cultures.
CONCLUSIONS: Differences in the levels of cx43 expression in leiomyoma and myometrial cells may reflect differences in responses to steroid hormones.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8238195     DOI: 10.1016/0002-9378(93)90293-r

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Oocyte-derived BMP15 but not GDF9 down-regulates connexin43 expression and decreases gap junction intercellular communication activity in immortalized human granulosa cells.

Authors:  Hsun-Ming Chang; Jung-Chien Cheng; Elizabeth Taylor; Peter C K Leung
Journal:  Mol Hum Reprod       Date:  2014-01-10       Impact factor: 4.025

2.  Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).

Authors:  Ussanee S Sangkomkamhang; Pisake Lumbiganon; Porjai Pattanittum
Journal:  Cochrane Database Syst Rev       Date:  2020-11-23

Review 3.  Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Authors:  Pasquapina Ciarmela; Md Soriful Islam; Fernando M Reis; Peter C Gray; Enrrico Bloise; Felice Petraglia; Wylie Vale; Mario Castellucci
Journal:  Hum Reprod Update       Date:  2011-07-25       Impact factor: 15.610

4.  Relaxin increases elastase activity and protease inhibitors in smooth muscle cells from the myometrium compared with cells from leiomyomas.

Authors:  Bertha Chen; Yan Wen; Xiao Yun Yu; Mary Lake Polan
Journal:  Fertil Steril       Date:  2008-06-12       Impact factor: 7.329

5.  Prolonged labour associated with lower expression of syndecan 3 and connexin 43 in human uterine tissue.

Authors:  Ann Hjelm Cluff; Birgitta Byström; Aurelija Klimaviciute; Camilla Dahlqvist; Gvido Cebers; Anders Malmström; Gunvor Ekman-Ordeberg
Journal:  Reprod Biol Endocrinol       Date:  2006-05-04       Impact factor: 5.211

6.  Progesterone Via its Type-A Receptor Promotes Myometrial Gap Junction Coupling.

Authors:  Lubna Nadeem; Oksana Shynlova; Sam Mesiano; Stephen Lye
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

7.  Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma.

Authors:  Anna Egorova; Sofia Shtykalova; Alexander Selutin; Natalia Shved; Marianna Maretina; Sergei Selkov; Vladislav Baranov; Anton Kiselev
Journal:  Pharmaceutics       Date:  2021-02-02       Impact factor: 6.321

8.  Polycondensed Peptide Carriers Modified with Cyclic RGD Ligand for Targeted Suicide Gene Delivery to Uterine Fibroid Cells.

Authors:  Anna Egorova; Sofia Shtykalova; Marianna Maretina; Alexander Selutin; Natalia Shved; Dmitriy Deviatkin; Sergey Selkov; Vladislav Baranov; Anton Kiselev
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.